ATS Corporation Conference Call Summary Company Overview - **Company**: ATS Corporation (NYSE: ATS) - **Date**: November 18, 2025 - **Speaker**: Ryan McLeod, Interim CEO Key Points Industry and Market Dynamics - **Life Sciences Sector**: ATS has six independent life science businesses, with a focus on automation and drug delivery mechanisms, particularly auto injectors, which account for approximately 10% of total revenues and 20% of life science revenues [7][15][16] - **Growth in GLP-1 Market**: The GLP-1 segment is expected to remain a significant revenue contributor over the next five years, with high growth potential due to increasing consumer demand for drug delivery devices [15][23] - **Radiopharma Growth**: Investment in radiopharmaceuticals for cancer treatment is driving growth, with a shift towards personalized medicine leading to more specific therapies [17][18] - **Wearable Devices**: ATS is involved in the development of wearable devices, expanding their market from diabetes treatment to general consumer applications [19][20] Financial Performance - **Q2 Fiscal Results**: Revenues increased by approximately 12% year-over-year, with a backlog growth of 13.5% [11][12] - **Margin Expansion**: ATS is on track for high single-digit organic growth and has seen sequential margin expansion, particularly in Q2 [12][13] - **Transportation Segment**: The transportation business has stabilized at around $50 million per quarter, with no expected growth in the next three to five years due to market saturation and technology changes [30][31] Strategic Initiatives - **Restructuring and Optimization**: ATS has undergone significant restructuring to optimize performance, particularly in the transportation segment, while exploring adjacent opportunities in industrial manufacturing and reshoring [31][33] - **Nuclear Business Growth**: The nuclear segment is expected to grow, with a focus on refurbishment, decommissioning, and new builds, particularly in the context of increasing energy demands [25][27][28] Leadership Transition - **CEO Search**: The board is actively engaged in the search for a new CEO, prioritizing candidates with strong backgrounds in continuous improvement and M&A [56][59] Other Considerations - **Working Capital Management**: ATS aims to reduce working capital investment from approximately 18% to a target of 15% of sales, with larger life science programs expected to contribute to this goal [46][48] - **Market Positioning**: ATS is focused on high-consequence markets such as life sciences and food, which are less cyclical and emphasize quality and time to market [44][45] This summary encapsulates the key insights from the ATS Corporation conference call, highlighting the company's strategic focus, market dynamics, and financial performance.

Financial Data and Key Metrics Changes - Order bookings were $734 million, up 6% sequentially, reflecting solid performance across diversified end markets [4] - Q2 revenues were $729 million, up 19% from Q2 last year, driven primarily by organic growth [4][12] - Adjusted earnings from operations in Q2 were $79 million, a 40% increase from the prior year [12] - Gross margin for Q2 was 29.9%, a 36 basis point increase from Q2 last year [12] Business Line Data and Key Metrics Changes - Life sciences order backlog at quarter end remains strong at $1.1 billion, supported by demand across sub-markets [4] - Food and beverage backlog was $218 million, with customer wins in multiple regions during Q2 [6] - Energy order backlog was a record $277 million, up 154% over Q2 last year, driven primarily by nuclear refurbishment projects [7] - The services business performed strongly, contributing to overall growth [24] Market Data and Key Metrics Changes - The nuclear funnel continues to broaden, covering service and new nuclear reactor builds, including small modular reactors [8] - The consumer products funnel remains stable, with ongoing programs in personal care and household goods packaging [8] - Transportation opportunities are smaller compared to previous years, but still present [8] Company Strategy and Development Direction - The company is focused on continuous improvement through the ATS Business Model, emphasizing value creation across its diversified global portfolio [3] - The company is actively cultivating and reviewing M&A opportunities that align with long-term strategic priorities [10] - Investment in innovation remains a core strategy, with the development of the Illuminate Manufacturing Intelligence platform [10][11] Management's Comments on Operating Environment and Future Outlook - The macro environment remains dynamic, with geopolitical tensions and trade considerations impacting operations [15] - The company expects to maintain leadership in key sub-markets and drive progress on growth priorities [16] - The outlook for sustained growth is supported by a strong order backlog and expectations for revenue and margin expansion in fiscal 2026 [17] Other Important Information - The company plans to incur approximately $15 million in restructuring costs in the latter half of the fiscal year, with an expected payback of less than one year [15] - The net debt-to-adjusted EBITDA ratio was 3.4 times, with expectations to reduce leverage to within the target range of 2-3 times [17] Q&A Session Summary Question: Concerns about slowing bookings momentum - Management noted that there is normal variability in bookings and a healthy book-to-bill ratio of 1.12, with strong activity in life sciences and food sectors [20][21] Question: Performance of the services business - The services business performed strongly, contributing positively to overall growth, and management confirmed plans to replace the head of that segment [24][25] Question: Margin trajectory and restructuring impact - Management expects margin expansion driven by both cost reduction initiatives and sales growth, with restructuring expected to yield cost savings [28][52] Question: Nuclear backlog and revenue conversion - The nuclear backlog is expected to grow, with refurbishment work continuing over the next 1.5 to 2 years, supplemented by new build projects [39][43] Question: Life sciences revenue performance - Revenue timing is largely driven by project execution in the backlog, with some exposure to publicly funded institutions being a small part of the business [50]

Financial Performance - Q2 2026 revenues increased by approximately 19% year-over-year to $728.5 million[17], including approximately 13% organic revenue growth[17] - Adjusted Earnings from Operations for Q2 2026 were $79.1 million, resulting in a 10.9% adjusted earnings from operations margin[17] - The company estimates Q3 F26 revenue to be in the range of $700 million to $740 million[20, 23] - Order Bookings for Q2 2026 reached $734 million, showing diversification across market verticals[17] Order Backlog and Book-to-Bill Ratio - Order Backlog increased by approximately 14% year-over-year to $2,070 million, providing good revenue visibility[17] - The trailing twelve-month book-to-bill ratio is healthy at 1.12 : 1[17] Market Outlook - Life Sciences Order Backlog is $1,144 million with a strong funnel including radiopharma and medical devices opportunities[18] - Food and Beverage Order Backlog is $218 million, driven by demand for primary and secondary processing solutions, plus packaging[18] - Energy Order Backlog is $277 million, supported by nuclear refurbishment projects in the near-term and new nuclear reactor builds in the mid- to longer-term[18] - Consumer Products Order Backlog is $245 million, supported by capabilities in warehouse automation and packaging[18]

ATS (ATS) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.45%. A quarter ago, it was expected that this automation services provider would post earnings of $0.27 per share when it actually produced earnings of $0.3, delivering a surprise of +11.11%.Over the last four quarters, the ...

Core Points - ATS Corporation will participate in the Baird 2025 Global Industrial Conference on November 11, 2025, with Ryan McLeod and Anne Cybulski representing the company [1][2] - The company will host a presentation at 12:35 p.m. (CT) and provide a webcast link for live viewing and replay for 180 days [2] - ATS Corporation is a leading automation solutions provider, serving various industries including life sciences, transportation, food & beverage, consumer products, and energy [3] Company Overview - Founded in 1978, ATS Corporation employs approximately 7,500 people across more than 65 manufacturing facilities and over 85 offices globally [3] - The company's shares are traded on the Toronto Stock Exchange and NYSE under the symbol ATS [3] - ATS specializes in custom automation, repeat automation, automation products, and value-added solutions, addressing complex manufacturing automation needs [3]

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) ("ATS†or the "Company†) will report its financial results for the second quarter ended September 28, 2025, before markets open on Wednesday November 05, 2025. At 8:30 a.m. Eastern on November 05, 2025, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/7. ...

ATS Corporation Conference Call Summary Company Overview - ATS Corporation is an automation company specializing in automation integration, products, and services, with a focus on providing turnkey solutions for customers launching new products [3][4][5] - The company operates across various industries, including life sciences (50% of business), food, energy (primarily nuclear), consumer applications, and transportation [5][6][7] Key Business Segments - **Life Sciences**: Major growth driver, particularly in auto injector assembly for GLP-1 drugs and other medical devices [18][19][21][22] - **Nuclear**: Involvement in life extension work for reactors, decommissioning, and new builds, including small modular reactors (SMRs) [25][27][30] - **Automation Services**: Comprises about 30% of the business, focusing on after-sales services, break-fix, spare parts, and digital consumables [6][58] Market Trends and Growth Drivers - **Supply Chain Resilience**: Customers are shifting towards onshoring and diversifying production locations to mitigate risks associated with geopolitical issues and supply chain disruptions [13][14][16] - **Automation Demand**: Increasing complexity and software-driven automation solutions are becoming essential across industries, particularly in life sciences and nuclear sectors [15][16] - **Recurring Revenue**: The company aims to increase its recurring revenue, currently around 30%, primarily from after-sales services [58][61] Financial Performance and Outlook - ATS has experienced a compound annual growth rate (CAGR) of approximately 17.5% in revenue outside of transportation over the past five years [12] - The company expects high single-digit growth for the current year, supported by a strong backlog and ongoing customer investments [36][37] - Targeting a 15% operating margin over the next four to five years, with ongoing initiatives to improve operational efficiency and expand higher-margin offerings [54][55] Mergers and Acquisitions Strategy - ATS focuses on acquiring companies in less cyclical markets like life sciences and food, emphasizing capabilities that enhance their technology and service offerings [46][49] - Financial criteria for acquisitions include a double-digit return on invested capital and EPS accretion [50] Competitive Landscape - ATS primarily competes with smaller, regional players in the automation space, rather than larger companies like Rockwell, which serves as a supplier [62][63] Additional Insights - The company is undergoing a CEO transition, with a focus on maintaining its continuous improvement culture and strategic direction during the search for a new leader [40][42][43] - The nuclear sector is viewed as a niche opportunity with significant potential for growth over the next five to ten years, particularly in automation for new reactor builds [30][56] Conclusion - ATS Corporation is well-positioned in the automation industry, with a diverse portfolio and strong growth prospects driven by market trends towards automation, supply chain resilience, and a focus on high-consequence industries. The company is committed to enhancing its operational efficiency and expanding its recurring revenue streams while navigating the competitive landscape and leadership transition.

Financial Data and Key Metrics Changes - Fiscal year 2025 was challenging, but financial results were supported by a diversified presence in dynamic end markets and disciplined application of the ATS business model [6][10] - ATS has outperformed the S&P 500 index on a total shareholder return basis over the past five years, despite global economic challenges [10] Business Line Data and Key Metrics Changes - In life sciences, ATS continues to support customers with automation solutions that enhance scalability and precision, with strategic investments driving innovation [7] - In food and beverage, ATS introduced advanced inspection and sorting solutions to improve quality control and operational efficiency [7] - The company strengthened its digital portfolio and service offerings, exploring AI-based tools integration across various markets [8] Market Data and Key Metrics Changes - ATS's specialized capabilities have shown steady progress across market verticals, including energy, where it assists nuclear customers in scaling operations to meet energy demands [7] - The transportation business has been better aligned with current end market demand following recent adjustments [9] Company Strategy and Development Direction - ATS is committed to continuous improvement and innovation, with a focus on leveraging the ATS business model as a competitive differentiator [8][39] - The company has made targeted acquisitions, such as Paxium and Heidolph, to expand capabilities in packaging and enhance its product suite [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its long-term strategy and drive sustained value creation through fiscal 2026 and beyond [10] - The leadership transition is expected to be smooth, with full confidence in the existing team to maintain progress [12][39] Other Important Information - The meeting included a leadership update, with Ryan McLeod appointed as interim CEO following Andrew Hyder's departure [12] - The board remains engaged with management to ensure risk management and value creation [8] Q&A Session Summary Question: Are there any questions from shareholders? - There were no questions submitted during the Q&A session, indicating a lack of immediate concerns from shareholders [41][42]

Financial Data and Key Metrics Changes - Q1 revenues were $737 million, up 6% from Q1 last year [6] - Order bookings were $693 million, down 15% compared to Q1 last year [16] - Adjusted earnings from operations in Q1 were CAD 78.6 million, representing 10.7% of revenues [18] - Gross margin for Q1 was 29.8%, consistent with Q1 last year [18] - Cash flows from operating activities were CAD 156 million [22] - Net debt to adjusted EBITDA ratio was 3.6 times on a pro forma basis at Q1 [22] Business Line Data and Key Metrics Changes - Life Sciences order backlog at quarter end was $1.2 billion, with strong contributions from auto injectors and radiopharma [7][8] - Food and Beverage backlog was $229 million, an increase of 6% compared to Q1 last year [10] - Energy business saw growth primarily in nuclear refurbishment activities, particularly around CANDU reactors [39] - Consumer Products and Transportation segments remained stable, with transportation experiencing lower EV end market demand [11][33] Market Data and Key Metrics Changes - The order backlog ended the quarter at approximately $2.1 billion, reflecting a healthy funnel across diversified offerings [6][19] - Orders in the energy sector, particularly nuclear, showed strong demand despite project delays reported by other companies [39] - Orders excluding transportation were up over 10% year-over-year in the first half of the calendar year [36] Company Strategy and Development Direction - The company is focused on driving growth through repeatable revenue from services, consumables, and digital offerings [7] - M&A activities are ongoing, with a focus on strategic opportunities that align with long-term growth ambitions [12][60] - The company aims to return leverage to its target range of 2 to 3 times while realizing synergies from recent acquisitions [23][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth outlook for the year, supported by a strong backlog and healthy order intake [35] - The company is closely monitoring the business environment, particularly regarding cross-border tariffs, but has not seen a material impact to date [20] - Management highlighted ongoing efficiency improvements and a commitment to creating long-term value for shareholders [25][60] Other Important Information - ATS was included in Time Magazine's inaugural list of Canada's Best Companies 2025, ranking number one in the engineering, manufacturing, and medical technology category [15] - The company continues to invest in innovation and capability development, including the launch of a new virtual reality training platform [13] Q&A Session Summary Question: Can you discuss the demand environment further? - Management noted that the trailing twelve-month book-to-bill ratio is 1.17, indicating alignment with growth targets and a healthy funnel across key markets [32] Question: What is driving the uptick in the energy business? - The growth in the energy sector is primarily driven by nuclear refurbishment activities, particularly around CANDU reactors [39] Question: Can you provide an update on the integration process and cross-selling opportunities? - Integration across recent acquisitions is progressing well, with strong uptake of ABM deployments and cost synergies being realized [52] Question: How is the company addressing the impact of U.S. government funding changes on lab research? - The impact is minimal, representing a low single-digit percentage of the overall business, and does not materially affect the life sciences segment [53] Question: What is the outlook for margin progression? - Management expects margin expansion throughout the year, although variability is anticipated due to project portfolio dynamics [85] Question: Can you elaborate on the Multiflex system? - The Multiflex system is designed for decommissioning nuclear reactors, enhancing efficiency and space management in the process [97]

Financial Data and Key Metrics Changes - Q1 revenues were $737 million, up 6% from Q1 last year [5] - Order bookings were $693 million, down 15% compared to Q1 last year [16] - Adjusted earnings from operations in Q1 were CAD 78.6 million, representing 10.7% of revenues [18] - Gross margin for Q1 was 29.8%, consistent with Q1 last year [18] - Cash flows from operating activities were CAD 156 million [22] - Net debt to adjusted EBITDA ratio was 3.6 times on a pro forma basis at Q1 [22] Business Line Data and Key Metrics Changes - In Life Sciences, order backlog at quarter end was $1.2 billion, with strong contributions from auto injectors and blood glucose monitoring wearables [6] - Food and Beverage backlog was $229 million, an increase of 6% compared to Q1 last year [8] - Energy sector saw growth primarily in nuclear refurbishment activities, particularly around CANDU reactors [42] - Consumer Products and Transportation sectors remained stable, with transportation experiencing lower EV end market demand [10] Market Data and Key Metrics Changes - The order backlog ended the quarter at approximately $2.1 billion, reflecting a healthy funnel across diversified offerings [5] - Orders in the first half of the calendar year were up over 10% year over year, excluding transportation [39] Company Strategy and Development Direction - The company is focused on returning leverage to its target range of 2 to 3 times and realizing further synergies from recent acquisitions [12][23] - The strategy includes growing repeatable revenue through services, consumables, and digital offerings [6] - The company remains committed to creating long-term value for shareholders and customers through strong execution and continued growth in targeted markets [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth outlook for the year, supported by a strong backlog and a trailing twelve-month book-to-bill ratio of 1.17 [33] - The company is closely monitoring the business environment due to cross-border tariffs but has not seen a material impact to date [20] - Management noted that while some customers in the lab research space are taking a more measured approach to capital spending, the overall outlook for Life Sciences remains positive [7] Other Important Information - ATS was included in Time Magazine's inaugural list of Canada's Best Companies 2025, ranking number one in the engineering, manufacturing, and medical technology category [14] - The company is actively engaged in M&A opportunities that align with long-term growth ambitions [11] Q&A Session Summary Question: Can you discuss the demand environment further? - Management noted that the trailing twelve-month book-to-bill ratio is 1.17, indicating alignment with growth targets and a healthy funnel of customer conversations [33][34] Question: What is driving the uptick in the energy business? - The growth in the energy sector is primarily driven by nuclear refurbishment activities, particularly around CANDU reactors, with a strong demand environment [42] Question: Can you provide an update on the integration process and cross-selling opportunities? - Integration across recent acquisitions is progressing well, with strong uptake in ABM deployments and cost synergies being realized [54] Question: How is the company addressing the impact of U.S. government funding changes on Life Sciences? - The impact is low, representing less than a single-digit percentage of the business, and has not materially affected overall Life Sciences performance [55] Question: What is the outlook for margin progression? - Management expects margin expansion for the year, driven by gross margin improvements and operational efficiencies, though variability is anticipated [88] Question: What is the status of the M&A pipeline during the leadership transition? - The company continues to pursue both organic and acquisition-related growth, with M&A activity ongoing despite the leadership transition [62]